enVVeno Medical Corporation
Organization details
- Legal name
- enVVeno Medical Corporation
- Former names
- Hancock Jaffe Laboratories, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Irvine
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NVNO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001661053
- EIN
- 33-0936180
Board of directors
-
Francis Duhay · DirectorSince 2023
-
Matthew Jenusaitis · DirectorSince 2023
-
Robert Andrew Berman · Director · Chief Executive OfficerSince 2023
-
Robert Gray · DirectorSince 2023
-
Sanjay Shrivastava · DirectorSince 2023
Chief executives
Director election results
Annual meeting of December 11, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
65.9%
-
89.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $4,944
- 4 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 11, 2026 | Francis Duhay Director | Open-market sale | −11 | $11.21 | $123 |
| Jun 11, 2026 | Francis Duhay Director | Open-market sale | −140 | $10.31 | $1,443 |
| Mar 12, 2026 | Francis Duhay Director | Open-market sale | −140 | $11.52 | $1,613 |
| Dec 11, 2025 | Francis Duhay Director | Open-market sale | −4,900 | $0.36 | $1,764 |
| Sep 15, 2025 | Francis Duhay Director | Open-market sale | −4,900 | $0.83 | $4,067 |
| Dec 31, 2024 | Francis Duhay Director | Open-market purchase | +81,433 | $3.07 | $249,999 |
| Dec 31, 2024 | Robert Gray Director | Open-market purchase | +3,500 | $2.94 | $10,290 |
| Dec 24, 2024 | Sanjay Shrivastava Director | Open-market purchase | +5,400 | $2.90 | $15,660 |
| Dec 19, 2024 | Matthew Jenusaitis Director | Open-market purchase | +9,620 | $2.53 | $24,339 |
| Dec 19, 2024 | Robert Andrew Berman Director, Officer (Chief Executive Officer) | Open-market purchase | +12,000 | $2.55 | $30,600 |
| Mar 13, 2024 | Alavi Hamed Officer (Chief Technology Officer) | Option exercise | +8,334 | $3.59 | $29,919 |
| Mar 13, 2024 | Alavi Hamed Officer (Chief Technology Officer) | Open-market sale | −8,334 | $6.22 | $51,837 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about enVVeno Medical Corporation
Who is the CEO of enVVeno Medical Corporation?
Robert Andrew Berman is enVVeno Medical Corporation's Chief Executive Officer.
How many directors are on enVVeno Medical Corporation's board?
enVVeno Medical Corporation's board has 5 directors: Francis Duhay, Matthew Jenusaitis, Robert Andrew Berman, Robert Gray and Sanjay Shrivastava.
Are enVVeno Medical Corporation insiders buying or selling shares?
Over the last 12 months, enVVeno Medical Corporation insiders made no open-market purchases and sold $4,944 of shares in 4 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="envveno-medical-corporation"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.